Sign In
Buy SGEN
$228.74
+0 (+0%)
At Close: Mar 12, 2024
Pfizer expects to close Seagen deal on Thursday, will create a new oncology division to incorporate company
06:59am, Tuesday, 12'th Dec 2023
Pfizer Inc. PFE, -0.49% said Tuesday it has received all the regulatory approvals needed to close the acquisition of Seagen Inc. SGEN, +1.20% and expects to close the deal on Thursday. To address conc
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
06:45am, Tuesday, 12'th Dec 2023
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with r
BOTHELL, Wash.--(BUSINESS WIRE)-- #ASH23--Seagen Inc. (NASDAQ: SGEN) today announced that clinically meaningful progression-free survival (PFS), a secondary endpoint, was observed in a Phase 2 study e
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ad
Why Is Seattle Genetics (SGEN) Down 0.7% Since Last Earnings Report?
12:48pm, Friday, 01'st Dec 2023
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock?
Seagen's (SGEN) Combo Drug Expanded-Use sBLA Gets Priority Tag
09:01am, Friday, 01'st Dec 2023
Seagen (SGEN) and Astellas Pharma announce that the FDA has accepted the label expansion-seeking application for the Padcev/Keytruda combo under priority review to treat first-line bladder cancer.
– Results of pivotal confirmatory trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall survival and progression-free survival vs standard platinum contain
CPRI, SGEN, VMW: Why These 3 Stocks Are on the Tip of Bill Gross' Tongue
10:00am, Sunday, 05'th Nov 2023
Bill Gross, the eponymous Bond King, is wading into the stock market to advise investors. Worryingly, he pointed to an imminent fourth-quarter recession closing out 2023.
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (NASDAQ: SGEN) today announced the first presentation of data evaluating ADCETRIS® (brentuximab vedotin) in combination with an anti-PD-1 checkpoint inhib
This High-Yield Dividend Stock Is a Proven Wealth Creator
10:00am, Thursday, 02'nd Nov 2023
In 2023, the broader market has ignored the deep value proposition of most large-cap pharmaceutical stocks. Pfizer, a stalwart of the industry, has been among the group's worst performers this year.
Seagen 3Q revenue beat driven by jump in product sales
12:11pm, Wednesday, 01'st Nov 2023
Seagen reported mixed third quarter earnings, with revenue outperforming expectations on strong product sales growth as earnings fell short of estimates. The cancer-focused biotechnology company which
Pfizer wins unconditional EU antitrust okay for $43 bln Seagen buy
10:54am, Thursday, 19'th Oct 2023
U.S. pharmaceutical company Pfizer gained unconditional EU antitrust approval on Thursday for its proposed $43 billion acquisition of cancer drug maker Seagen.
5 Stocks That Have Massive Upside According to Analysts
11:06am, Friday, 29'th Sep 2023
Analyst ratings are not perfect, but they're one of the better ways for investors to forecast future stock price movement. Here are five stocks that analysts believe have massive upside for patient, l
Signal Says Buy Calls on This Biotech Stock
02:32pm, Monday, 25'th Sep 2023
Biotech stock Seagen Inc (NASDAQ:SGEN) scored an all-time high of $215.04 today, building on a Friday breakout from a consolidation between $204 and $210.
Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study
12:01pm, Monday, 25'th Sep 2023
Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company ris
